<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134861</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-9410</org_study_id>
    <secondary_id>U10CA021661</secondary_id>
    <secondary_id>CDR0000063640</secondary_id>
    <nct_id>NCT01134861</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>A Three-Arm Phase III Study of Concomitant Versus Sequential Chemotherapy and Thoracic Radiotherapy for Patients With Locally Advanced Inoperable Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug and combining chemotherapy with
      radiation therapy may kill more tumor cells.

      PURPOSE: Randomized phase III trial to compare the effectiveness of various schedules of
      radiation therapy and combination chemotherapy using vinblastine and cisplatin or cisplatin
      and etoposide in treating patients with stage II or stage III non-small cell lung cancer that
      cannot be removed surgically.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the survival rate of patients with locally advanced, unresectable
      non-small cell lung cancer randomized to concomitant vinblastine/cisplatin (VBL/CDDP) and
      thoracic radiotherapy versus sequential VBL/CDDP and once-daily thoracic radiotherapy. II.
      Compare the survival rate of such patients randomized to 2 courses of concomitant
      etoposide/cisplatin and hyperfractionated thoracic radiotherapy versus sequential VBL/CDDP
      and once-daily thoracic radiotherapy. III. Assess the frequency of treatment-related
      esophageal and hematologic toxicity/morbidity in patients on concomitant versus sequential
      chemoradiation treatment arms.

      OUTLINE: Randomized study. The following acronyms are used: CDDP Cisplatin, NSC-119875 VBL
      Vinblastine, NSC-49842 VP-16 Etoposide, NSC-141540 Arm I: 2-Drug Combination Chemotherapy
      Followed by Radiotherapy. CDDP/VBL; followed by thoracic irradiation using photons of at
      least 6 MV (electrons may be used to boost the supraclavicular lymph nodes). Arm II:
      Radiotherapy plus 2-Drug Combination Chemotherapy. Thoracic irradiation using equipment as in
      Arm I; plus CDDP/VBL. Arm III: Hyperfractionated Radiotherapy plus 2-Drug Combination
      Chemotherapy. Thoracic irradiation using equipment as in Arm I; plus CDDP/VP-16.

      PROJECTED ACCRUAL: A total of 597 patients will be entered over 3.1-4.2 years. If fewer than
      6 patients/month are accrued, the feasibility of the study will be re-evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1994</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 1998</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from date of randomization to date of death or last follow-up for patients still alive</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">610</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Sequential ChemoRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vinblastine 6 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 &amp; 29 RT: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Concurrent STD RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinblastine 5 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 &amp; 29 RT: 63 GY/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Concurrent HFX RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral VP-16 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40 (76 mg/day if BSA &lt; 1.7m2) Cisplatin 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36 RT: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>100 mg/m2 i.v. over 30-60 minutes, days 1 &amp; 29</description>
    <arm_group_label>Arm 1: Sequential ChemoRT</arm_group_label>
    <arm_group_label>Arm 2: Concurrent STD RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area &lt; 1.7 m2</description>
    <arm_group_label>Arm 3: Concurrent HFX RT</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>5 mg/m2 i.v. bolus weekly first 5 weeks of RT</description>
    <arm_group_label>Arm 1: Sequential ChemoRT</arm_group_label>
    <arm_group_label>Arm 2: Concurrent STD RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment</description>
    <arm_group_label>Arm 1: Sequential ChemoRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36</description>
    <arm_group_label>Arm 3: Concurrent HFX RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment</description>
    <arm_group_label>Arm 2: Concurrent STD RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy</description>
    <arm_group_label>Arm 3: Concurrent HFX RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Locoregionally advanced, inoperable, non-small cell lung cancer
        with no evidence of distant metastases, i.e.: Stage II/IIIA medically inoperable disease
        Stage IIIA/IIIB unresectable disease No pleural effusion Appearance after an invasive
        thoracic procedure allowed No more than 5% weight loss within 3 months prior to diagnosis
        Confirmed N2 disease should first be evaluated for protocol RTOG-9309

        PATIENT CHARACTERISTICS: Age: At least 18 Performance status: Karnofsky 70%-100%
        Hematopoietic: AGC at least 2,000 Platelets at least 100,000 Hemoglobin at least 8.0 g/dL
        Hepatic: (unless abnormality caused by benign disease) Bilirubin no more than 1.5 times
        normal AST no more than 1.5 times normal Renal: Creatinine no more than 1.5 mg/dL
        Cardiovascular: No myocardial infarction within the past 6 months No angina No congestive
        heart failure No uncontrolled arrhythmia Other: No synchronous or prior invasive malignancy
        within 3 years except nonmelanomatous skin cancer No pregnant women Effective contraception
        required of fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior thoracic or neck
        radiotherapy Surgery: No prior complete or nearly complete tumor resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter J. Curran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <reference>
    <citation>Siddiqui F, Bae K, Langer CJ, Coyne JC, Gamerman V, Komaki R, Choy H, Curran WJ, Watkins-Bruner D, Movsas B. The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials. J Thorac Oncol. 2010 May;5(5):631-9.</citation>
    <PMID>20432520</PMID>
  </reference>
  <reference>
    <citation>Konski AA, Bhargavan M, Owen J, et al.: &quot;Less is not always more&quot;: an economic analysis of Radiation Therapy Oncology Group 94-10. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-1080, S182, 2007.</citation>
  </reference>
  <reference>
    <citation>Choy H, Swann S, Nabid A, et al.: Comparison of 5-year survival between RTOG-94-10 and a phase 2 study of induction chemotherapy followed by efaproxiral + radiotherapy in patients with locally advanced NSCLC. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-49, S28-9, 2006.</citation>
  </reference>
  <reference>
    <citation>Bradley J. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol. 2005 Apr;32(2 Suppl 3):S111-3. Review.</citation>
    <PMID>16015546</PMID>
  </reference>
  <reference>
    <citation>Langer CJ, Swann S, Curran W, et al.: Reassessing prognostic factors in the era of combined modality therapy for locally advanced NSCLC: a retrospective analysis of RTOG 9410 and 9801. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-65, S39, 2005.</citation>
  </reference>
  <reference>
    <citation>Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):667-71. Epub 2005 May 31.</citation>
    <PMID>15927409</PMID>
  </reference>
  <reference>
    <citation>Machtay M, Swann S, Komaki R, et al.: Overall treatment time during concurrent chemoradiotherapy and outcomes: an RTOG secondary analysis. [Abstract] Lung Cancer 50 (Suppl 2): A-O-042, S17, 2005.</citation>
  </reference>
  <reference>
    <citation>Machtay M, Swann S, Komaki R, et al.: What is the meaning of local-regional control after chemoradiation for locally advanced NSCLC? An RTOG analysis. [Abstract] Lung Cancer 50 (Suppl 2): A-O-041, S17, 2005.</citation>
  </reference>
  <reference>
    <citation>Swann RS, Machtay M, Komaki R, et al.: Impact of overall treatment time during concurrent chemoradiotherapy for locally advanced NSCLC: an RTOG secondary analysis. [Abstract] J Clin Oncol 23 (Suppl 16): A-7061, 635s, 2005.</citation>
  </reference>
  <reference>
    <citation>Werner-Wasik M, Scott C, Curran WJ, et al.: Correlation between acute esophagitis and late pneumonitis in patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent thoracic radiotherapy (RT) and chemotherapy: a multivariate analysis of the Radiation Therapy Oncology Group (RTOG) database. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1192, 2002.</citation>
  </reference>
  <reference>
    <citation>Sause W, Scott C, Byhardt R, et al.: Combined chemotheray radiation therapy treatment in unresected non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) experience. Lung Cancer 29(suppl 2): 2000.</citation>
  </reference>
  <results_reference>
    <citation>Curran WJ, Scott CB, Langer CJ, et al.: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2499, 2003.</citation>
  </results_reference>
  <results_reference>
    <citation>Langer CJ, Hsu C, Curran WJ, et al.: Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1193, 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>Langer CJ, Hsu C, Curran W, et al.: Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? A secondary analysis of RTOG 94-10. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-36, 20-21, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>Movsas B, Scott C, Curran W, et al.: A quality-adjusted time without symptons or toxicity (QTWiST) analysis of Radiation Therapy Oncology Group (RTOG) 94-10. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1247, 313a, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>Curran WJ, Scott C, Langer C, et al.: Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1891, 2000.</citation>
  </results_reference>
  <results_reference>
    <citation>Komaki R, Seiferheld W, Curran W, et al.: Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). [Abstract] Int J Radiat Oncol Biol Phys 48 (3 suppl): A-5, 113, 2000.</citation>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

